Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5803407 | 0.84 | KCNH2 (0.33) | ALDH1A1MEN1KMT2A | |
| SCHEMBL5801604 | 0.84 | KCNH2 (0.33) | ALDH1A1MEN1KMT2A | |
| SCHEMBL3570280 | 0.80 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL5803044 | 0.75 | KMT2A (0.35) | MEN1KMT2AOPRM1 | |
| SCHEMBL3564406 | 0.74 | — | — | |
| SCHEMBL5912951 | 0.73 | POLB (0.30) | — | |
| SCHEMBL3566488 | 0.72 | MDM2 (0.31) | KMT2A | |
| SCHEMBL3570078 | 0.71 | TRPM8 (0.34) | ALDH1A1TRPM8MEN1KMT2AS1PR3 | |
| SCHEMBL3573280 | 0.70 | CNR2 (0.32) | MEN1KMT2A | |
| SCHEMBL3564557 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160790-A1 | Thioureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | claimed |
| WO-2006063293-A2 | THIOUREAS AS FACTOR Xa INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | claimed |
| US-20060160790-A1 | Thioureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006063293-A2 | THIOUREAS AS FACTOR Xa INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160790-A1 | Thioureas as factor Xa inhibitors | TFPI, TFPI2, F12 | ALDH1A1 633/4885SMN1; SMN2 4420/4885LMNA 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.